reports
- Martial Descoutures
- Roland Pfaender
- MBA
- CFA
- CCRA
- Ana Arjona-Martinez
- Yan Derocles
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant Announces Pricing of $550 Million Common Stock Financing Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connectio...
Olympic Steel Inc: 1 director
A director at Olympic Steel Inc maiden bought 5,030 shares at 39.890USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Rok Stibric
Alta Equipment Group Inc: 1 director
A director at Alta Equipment Group Inc bought 40,000 shares at 5.074USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Ana Arjona-Martinez
- Yan Derocles
- ABGSC Capital Goods Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
FBG Holdings Berhad: 4 directors
Three Directors at FBG Holdings Berhad subscribed to 68,045,625 shares at 0.180MYR. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Basilea und Phare Bio gehen Partnerschaft zur Entwicklung eines neuart...
Basilea und Phare Bio gehen Partnerschaft zur Entwicklung eines neuartigen Antibiotikums ein - Kombination von industrieller Expertise und einzigartigen KI-Fähigkeiten Allschwil, 11. Dezember 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass es eine Partnerschaft mit Phare Bio Inc., Boston (USA), eingegangen ist, einem sozial engagierten Biotech-Unternehmen, das Künstliche Intelligenz (KI)...
Basilea and Phare Bio enter partnership combining anti-infectives indu...
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a partnership with Phare Bio Inc., Boston (USA), a biotech social venture that uses Artificial Intelligence (AI) to accelerate antibiotic discovery and development. Under the partnership, Phare Bio w...
HBL Corporation: 1 director
A director at HBL Corporation sold 70,000 shares at 5,101.143KRW and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Capri Holdings Ltd: 1 director
A director at Capri Holdings Ltd sold 10,000 shares at 25.961USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a g...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research si...
Laurent Nielly appointed as successor to CEO Gustavo Calvo Paz
Laurent Nielly appointed as successor to CEO Gustavo Calvo Paz Inside / regulated information Aalst, Belgium, December 11, 2025 – The Board of Directors of Ontex (Euronext: ONTEX) has decided to appoint Mr. Laurent Nielly as Chief Executive Officer, effective as from the end of Mr. Gustavo Calvo Paz’s mandate as Chief Executive Officer at Ontex’s next annual shareholders’ meeting, on May 5, 2026. Since 2021, Mr. Nielly has been President of Ontex’s Europe Division, leading our retailer brands and healthcare business across Europe. Prior to that, Mr. Nielly led Ontex’s business in Brazil....
Laurent Nielly benoemd tot opvolger van CEO Gustavo Calvo Paz
Laurent Nielly benoemd tot opvolger van CEO Gustavo Calvo Paz Voorkennis / gereglementeerde informatie Aalst, België, 11 december 2025 – De Raad van Bestuur van Ontex (Euronext: ONTEX) heeft besloten om de heer Laurent Nielly te benoemen tot Chief Executive Officer, met ingang vanaf het einde van het mandaat van de heer Gustavo Calvo Paz als Chief Executive Officer, dat afloopt op de volgende algemene aandeelhoudersvergadering van Ontex op 5 mei 2026. Sinds 2021 is de heer Nielly President van de Europese Divisie van Ontex, waar hij de leiding heeft over onze retailmerken en onze gezondhe...
Zealand Pharma and OTR Therapeutics enter multi-program strategic coll...
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets...
Addex Amends its at the Market Offering Agreement With H.C. Wainwright...
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) initially entered into on January 30, 2024. The at-the-market offering program enables A...
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expandi...
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a yearCablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.